First Biologic Therapy for Chronic Obstructive Pulmonary Disease in the U.S.

  • FDA approves expanded use of Dupixent for COPD treatment
  • First biologic therapy for lung disease in the U.S.
  • Regeneron and Sanofi collaborate on drug development and marketing

The FDA has approved an expanded use of Dupixent, a blockbuster anti-inflammatory drug developed by Regeneron and Sanofi, for treating chronic obstructive pulmonary disease (COPD). This makes it the first biologic therapy for lung disease in the U.S., which makes it difficult to breathe. The European Union approved Dupixent for COPD in July, and both companies also received regulatory approval from China earlier this week. Regeneron, a Tarrytown, N.Y.-based biotechnology company, created Dupixent and markets it jointly with France’s Sanofi in the U.S., while Sanofi handles international marketing. The drug generated approximately $11.6 billion in sales last year.

Factuality Level: 8
Factuality Justification: The article provides accurate and relevant information about the FDA’s approval of Dupixent for COPD and its significance as the first biologic therapy for the condition. It also mentions the companies involved in the development and marketing of the drug, along with its sales figures from the previous year.
Noise Level: 3
Noise Justification: The article provides relevant information about the FDA’s approval of Dupixent for COPD and its significance as the first biologic therapy for the condition. However, it lacks in-depth analysis or exploration of long-term trends or consequences, and does not offer actionable insights or new knowledge beyond the basic facts.
Public Companies: Regeneron Pharmaceuticals (REGN), Sanofi (SAN)
Key People: Colin Kellaher (Writer)

Track all markets on TradingView

Financial Relevance: Yes
Financial Markets Impacted: Pharmaceutical companies Regeneron and Sanofi
Financial Rating Justification: The article discusses the approval of Dupixent, a blockbuster anti-inflammatory drug for chronic obstructive pulmonary disease (COPD), which impacts the financial markets and companies involved in its development and sales. This is relevant to financial topics as it affects the revenue and stock prices of Regeneron and Sanofi.
Presence Of Extreme Event: No
Nature Of Extreme Event: Other
Impact Rating Of The Extreme Event: Minor
Extreme Rating Justification: There is no extreme event mentioned in the article, and it focuses on the approval of Dupixent for COPD by the U.S. Food and Drug Administration and European Union regulators.
Move Size: No market move size mentioned.
Sector: Healthcare
Direction: Up
Magnitude: Large
Affected Instruments: Stocks

Reported publicly: www.wsj.com www.marketwatch.com